Fusion Pharmaceuticals announced a patent dispute settlement and new licensing agreement with Heidelberg University and Euratom for exclusive, worldwide rights to their existing patent for FPI-2265, an actinium-225-based targeted radiotherapy for the treatment of prostate-specific membrane antigen (PSMA)-expressing cancers.
In the announcement, Fusion spokesperson Mohit Rawat said the company's radiopharmaceutical manufacturing facility is positioned to advance FPI-2265. Fusion also plans to release the results of its targeted alpha therapies TATCIST study in April, as well as initiate a phase II/III registrational study, Rawat said. Fusion has signed strategic actinium supply agreements with Niowave and BWXT Medical.
Under the terms of the license agreement, Fusion will pay approximately $1 million, in addition to certain regulatory milestones upon potential approval and low single-digit royalties on future net sales of applicable products.
